Badanie oceniające skuteczność i bezpieczeństwo stosowania anifrolumabu u osób dorosłych z przewlekłym i/lub podostrym toczniem rumieniowatym skórnym (LAVENDER)
Wieloośrodkowe, randomizowane, podwójnie ślepe, kontrolowane placebo badanie fazy III mające na celu ocenę skuteczności i bezpieczeństwa stosowania anifrolumabu u osób dorosłych z przewlekłym i/lub podostrym toczniem rumieniowatym skórnym, opornych na leczenie przeciwmalaryczne i/lub nietolerujących terapii przeciwmalarycznej
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Cape Town, Afryka Południowa, 7500
- Research Site
-
Johannesburg, Afryka Południowa, 2193
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires, Argentyna, 1221
- Research Site
-
Córdoba, Argentyna, 5000
- Research Site
-
Córdoba, Argentyna, X5004BAL
- Research Site
-
Quilmes, Argentyna, 1878
- Research Site
-
San Miguel, Argentyna, 1663
- Research Site
-
-
-
-
-
Kogarah, Australia, 3168
- Research Site
-
Melbourne, Australia, 3004
- Research Site
-
Mitcham, Australia, 3132
- Research Site
-
Westmead, Australia, 2145
- Research Site
-
Woolloongabba, Australia, 04102
- Research Site
-
-
-
-
-
Graz, Austria, 8036
- Research Site
-
Innsbruck, Austria, 6020
- Research Site
-
Linz, Austria, 4020
- Research Site
-
Vienna, Austria, 1130
- Research Site
-
-
-
-
-
Belo Horizonte, Brazylia, 30150-221
- Research Site
-
Porto Alegre, Brazylia, 90035903
- Research Site
-
Rio de Janeiro, Brazylia, 22470-220
- Research Site
-
Salvador, Brazylia, 40150-150
- Research Site
-
São Paulo, Brazylia, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bułgaria, 1784
- Research Site
-
Sofia, Bułgaria, 1463
- Research Site
-
Sofia, Bułgaria, 1528
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Changchun, Chiny, 130021
- Research Site
-
Changsha, Chiny, 410011
- Research Site
-
Chengdu, Chiny, 610021
- Research Site
-
Chongqing, Chiny, 400016
- Research Site
-
Dongguan, Chiny, 523059
- Research Site
-
Guangzhou, Chiny, 510120
- Research Site
-
Heilongjiang, Chiny, 150086
- Research Site
-
Jinan, Chiny, 250022
- Research Site
-
Shanghai, Chiny, 200025
- Research Site
-
Shanghai, Chiny, 200443
- Research Site
-
Shenzhen, Chiny, 518053
- Research Site
-
Shenzhen, Chiny, 518020
- Research Site
-
Shenzhen, Chiny, 518052
- Research Site
-
Zhuzhou, Chiny, 412007
- Research Site
-
Ürümqi, Chiny, CN-830004
- Research Site
-
-
-
-
-
Aarhus, Dania, 641-8510
- Research Site
-
Copenhagen, Dania, 2100
- Research Site
-
-
-
-
-
Iloilo City, Filipiny, 5000
- Research Site
-
Lipa, Filipiny, 4217
- Research Site
-
Manila, Filipiny, 1000
- Research Site
-
-
-
-
-
Bois-Guillaume, Francja, 76031
- Research Site
-
Dijon, Francja, 21000
- Research Site
-
Lyon, Francja, 69437
- Research Site
-
Montivilliers, Francja, 76290
- Research Site
-
Nantes, Francja, 44000
- Research Site
-
Paris, Francja, 75010
- Research Site
-
Paris, Francja, 75014
- Research Site
-
Paris, Francja, 75013
- Research Site
-
Paris, Francja, 75970
- Research Site
-
Poitiers, Francja, 86000, FR
- Research Site
-
Toulouse, Francja, 31059
- Research Site
-
-
-
-
-
Athens, Grecja, 12462
- Research Site
-
Athens, Grecja, 16121
- Research Site
-
-
-
-
-
Barcelona, Hiszpania, 8035
- Research Site
-
Barcelona, Hiszpania, 08025
- Research Site
-
Castellon, Hiszpania, 12004
- Research Site
-
Granada, Hiszpania, 18012
- Research Site
-
L'Hospitalet de Llobregat, Hiszpania, 08907
- Research Site
-
Las Palmas de Gran Canaria, Hiszpania, 35010
- Research Site
-
Madrid, Hiszpania, 28034
- Research Site
-
Madrid, Hiszpania, 28041
- Research Site
-
Madrid, Hiszpania, 28040
- Research Site
-
Madrid, Hiszpania, 28006
- Research Site
-
Majadahonda, Hiszpania, 28222
- Research Site
-
Salamanca, Hiszpania, 37007
- Research Site
-
Seville, Hiszpania, 41014
- Research Site
-
Valencia, Hiszpania, 46014
- Research Site
-
Valencia, Hiszpania, 46017
- Research Site
-
Vigo, Hiszpania, 36200
- Research Site
-
-
-
-
-
Breda, Holandia, 4818 CK
- Research Site
-
Rotterdam, Holandia, 3015 GD
- Research Site
-
-
-
-
-
Chūōku, Japonia, 104-8560
- Research Site
-
Fukuoka, Japonia, 812-8582
- Research Site
-
Kanazawa, Japonia, 920-8641
- Research Site
-
Kita-gun, Japonia, 761-0793
- Research Site
-
Nagoya, Japonia, 457-8510
- Research Site
-
Nagoya, Japonia, 467-8602
- Research Site
-
Wakayama, Japonia, 641-8510
- Research Site
-
Yokohama, Japonia, 232-0024
- Research Site
-
tabashi City, Japonia, 173-8606
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- Research Site
-
Toronto, Ontario, Kanada, M5T 2S8
- Research Site
-
-
-
-
-
Barranquilla, Kolumbia, 080020
- Research Site
-
Bogotá, Kolumbia, 110221
- Research Site
-
-
-
-
-
Seoul, Korea Południowa, 03080
- Research Site
-
Seoul, Korea Południowa, 06591
- Research Site
-
Seoul, Korea Południowa, 06973
- Research Site
-
-
-
-
-
Guadalajara, Meksyk, 44340
- Research Site
-
Guadalajara, Meksyk, 44610
- Research Site
-
Mexico City, Meksyk, 07760
- Research Site
-
Veracruz, Meksyk, 91910
- Research Site
-
-
-
-
-
Berlin, Niemcy, 10117
- Research Site
-
Bochum, Niemcy, 44791
- Research Site
-
Dresden, Niemcy, 01307
- Research Site
-
Erlangen, Niemcy, 91054
- Research Site
-
Essen, Niemcy, 45147
- Research Site
-
Freiburg im Breisgau, Niemcy, 79104
- Research Site
-
Hanover, Niemcy, 30625
- Research Site
-
Kiel, Niemcy, 24105
- Research Site
-
Leipzig, Niemcy, 04103
- Research Site
-
Mainz, Niemcy, 55131
- Research Site
-
Marburg, Niemcy, 35043
- Research Site
-
Regensburg, Niemcy, 93053
- Research Site
-
Wuppertal, Niemcy, 42283
- Research Site
-
-
-
-
-
Papatoetoe, Nowa Zelandia, 2025
- Research Site
-
-
-
-
-
Katowice, Polska, 40-851
- Research Site
-
Kielce, Polska, 25-316
- Research Site
-
Ossy, Polska, 40-027
- Research Site
-
Rzeszów, Polska, 35-055
- Research Site
-
Warsaw, Polska, 02-637
- Research Site
-
-
-
-
-
Braga, Portugalia, 4710-243
- Research Site
-
Lisbon, Portugalia, 1649-035
- Research Site
-
Porto, Portugalia, 4099-001
- Research Site
-
-
-
-
-
Bucharest, Rumunia, 020125
- Research Site
-
Iași, Rumunia, 700291
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Research Site
-
Kragujevac, Serbia, 34000
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85028
- Research Site
-
-
California
-
Covina, California, Stany Zjednoczone, 91722
- Research Site
-
La Jolla, California, Stany Zjednoczone, 92037
- Research Site
-
Los Angeles, California, Stany Zjednoczone, 90045
- Research Site
-
Los Angeles, California, Stany Zjednoczone, 90089
- Research Site
-
Orange, California, Stany Zjednoczone, 92868
- Research Site
-
San Francisco, California, Stany Zjednoczone, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33309
- Research Site
-
Miami, Florida, Stany Zjednoczone, 33174
- Research Site
-
Plantation, Florida, Stany Zjednoczone, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Research Site
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Research Site
-
Boston, Massachusetts, Stany Zjednoczone, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Research Site
-
Bloomfield Hills, Michigan, Stany Zjednoczone, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Stany Zjednoczone, 10028
- Research Site
-
Rochester, New York, Stany Zjednoczone, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28207
- Research Site
-
Statesville, North Carolina, Stany Zjednoczone, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22903
- Research Site
-
Roanoke, Virginia, Stany Zjednoczone, 24016
- Research Site
-
-
-
-
-
Košice, Słowacja, 04001
- Research Site
-
Piešťany, Słowacja, 92101
- Research Site
-
-
-
-
-
Bangkok, Tajlandia, 10330
- Research Site
-
Bangkok, Tajlandia, 10700
- Research Site
-
Hat Yai, Tajlandia, 90110
- Research Site
-
Khlong Luang, Tajlandia, 12120
- Research Site
-
Khon Kaen, Tajlandia, 40002
- Research Site
-
-
-
-
-
Kaohsiung City, Tajwan, 83301
- Research Site
-
Taichung, Tajwan, 404
- Research Site
-
Taipei, Tajwan, 10449
- Research Site
-
-
-
-
-
Cordaleo, Turcja (Türkiye), 35575
- Research Site
-
Istanbul, Turcja (Türkiye), 34098
- Research Site
-
Kayseri, Turcja (Türkiye), 38039
- Research Site
-
Samsun, Turcja (Türkiye), 55270
- Research Site
-
-
-
-
-
Brescia, Włochy, 25123
- Research Site
-
Cona, Włochy, 44124
- Research Site
-
Florence, Włochy, 50121
- Research Site
-
Milan, Włochy, 20132
- Research Site
-
Naples, Włochy, 80138
- Research Site
-
Reggio Emilia, Włochy, 42123
- Research Site
-
Roma, Włochy, 00144
- Research Site
-
Rome, Włochy, 00168
- Research Site
-
-
-
-
-
Cambridge, Zjednoczone Królestwo, CB2 0QQ
- Research Site
-
Leeds, Zjednoczone Królestwo, LS2 9JT
- Research Site
-
London, Zjednoczone Królestwo, NW1 2PG
- Research Site
-
London, Zjednoczone Królestwo, SE5 9RS
- Research Site
-
London, Zjednoczone Królestwo, SE1 7EH
- Research Site
-
London, Zjednoczone Królestwo, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Zjednoczone Królestwo, NE1 4LP
- Research Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Komparator placebo: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Ramy czasowe: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from baseline in total CLASI-A score
Ramy czasowe: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Ramy czasowe: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Ramy czasowe: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Ramy czasowe: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Ramy czasowe: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Ramy czasowe: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Ramy czasowe: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Ramy czasowe: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Ramy czasowe: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Ramy czasowe: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Ramy czasowe: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Ramy czasowe: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Ramy czasowe: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Ramy czasowe: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Ramy czasowe: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants with adverse events
Ramy czasowe: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- D346BC00001
- 2021-003698-70 (Numer EudraCT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Ramy czasowe udostępniania IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kryteria dostępu do udostępniania IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .